Skip to main content
Signal8
Launch Terminal

GENMAB A/S (GMAB)

Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Genmab A/S logo

Genmab A/S

NASDAQ:GMABHealthcare
+1.01%$57.06
AH$57.07+0.02%vs close
Mkt Cap$35.09B
Float614.22M
O/S614.9M
Vol
$ Vol
RVOL
Inst Own16.6%
SI1.1%
Earnings
Dilution
Genmab A/S logoNASDAQ:GMAB$57.06+1.01%
Upcoming Catalysts
Phase Distribution
68 lead-sponsored trials·31 active·10 completed
Phase 19
Phase 1/228
Phase 213
Phase 2/31
Phase 316
Not applicable1
(32 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Zalutumumab in Patients With Non-curable Head and Neck Cancer

    Zalutumumab

    Head and Neck Cancer, Squamous Cell Cancer

    Enrollment
    286
    Start
    Nov 2006
    Primary Completion
    Dec 2009
    Completion
    Aug 2011
    NCT00382031
  • Phase 3
    Active, not recruiting

    A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

    Epcoritamab, Investigator's Choice Chemotherapy

    Diffuse Large B-cell Lymphoma

    Enrollment
    483
    Start
    Jan 2021
    Primary Completion
    Oct 2025
    Completion
    Apr 2028est.
    NCT04628494
  • Phase 3
    Active, not recruiting

    Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

    Epcoritamab, Rituximab

    Follicular Lymphoma (FL)

    Enrollment
    549
    Start
    Sep 2022
    Primary Completion
    Dec 2029est.
    Completion
    Dec 2029est.
    NCT05409066
  • Phase 3
    Active, not recruiting

    A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

    Epcoritamab, Cyclophosphamide

    Diffuse Large B-Cell Lymphoma

    Enrollment
    900
    Start
    Feb 2023
    Primary Completion
    Jun 2027est.
    Completion
    Dec 2029est.
    NCT05578976
  • Phase 3
    Active, not recruiting

    Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

    Epcoritamab, Prednisone

    Follicular Lymphoma (FL)

    Enrollment
    1,095
    Start
    Feb 2024
    Primary Completion
    Nov 2037est.
    Completion
    Nov 2037est.
    NCT06191744
  • Phase 3
    Active, not recruiting

    A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Epcoritamab, Rituximab

    Diffuse Large B-Cell Lymphoma

    Enrollment
    379
    Start
    Aug 2024
    Primary Completion
    Mar 2028est.
    Completion
    Mar 2028est.
    NCT06508658
  • Phase 3
    Active, not recruiting

    Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

    Rina-S, Paclitaxel

    Platinum-resistant Ovarian Cancer

    Enrollment
    584
    Start
    Feb 2025
    Primary Completion
    Aug 2026READOUT • p=0.000
    Completion
    Oct 2027est.
    NCT06619236
  • Phase 3
    Active, not recruiting

    Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

    Acasunlimab, Pembrolizumab

    PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

    Enrollment
    191
    Start
    Nov 2024
    Primary Completion
    Jul 2027est.
    Completion
    Sep 2028est.
    NCT06635824
  • Phase 3
    Recruiting

    Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

    Rina-S, IC

    Endometrial Cancer, Recurrent or Progressive Endometrial Cancer

    Enrollment
    660
    Start
    Nov 2025
    Primary Completion
    Aug 2029est.
    Completion
    Nov 2029est.
    NCT07166094
  • Phase 3
    Recruiting

    Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

    Rina-S, Bevacizumab

    Ovarian Cancer, Platinum-sensitive Ovarian Cancer +1

    Enrollment
    544
    Start
    Apr 2026
    Primary Completion
    Oct 2028est.
    Completion
    May 2030est.
    NCT07225270
  • Phase 3
    Active, not recruiting

    A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

    Epcoritamab, Investigator's Choice Chemotherapy

    Diffuse Large B-Cell Lymphoma

    Enrollment
    72
    Start
    Oct 2022
    Primary Completion
    Oct 2025
    Completion
    Jun 2028est.
    NCT07226752
  • Phase 3
    Recruiting

    Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

    Rina-S, Bevacizumab

    Platinum-Sensitive Ovarian Cancer, Ovarian Cancer

    Enrollment
    688
    Start
    Aug 2026
    Primary Completion
    Dec 2029est.
    Completion
    Nov 2031est.
    NCT07564141
  • Phase 3
    Recruiting

    An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

    Rina-S, Paclitaxel

    Platinum-resistant Ovarian Cancer

    Enrollment
    82
    Start
    Jun 2026
    Primary Completion
    Sep 2027est.
    Completion
    Dec 2028est.
    NCT07604766
  • Phase 3
    Recruiting

    Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

    Petosemtamab, Cetuximab

    Left-sided Colorectal Cancer

    Enrollment
    960
    Start
    Aug 2026
    Primary Completion
    Jul 2029est.
    Completion
    Sep 2031est.
    NCT07702032
  • Phase 3
    Recruiting

    Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

    Petosemtamab, Cetuximab

    Colorectal Cancer

    Enrollment
    600
    Start
    Oct 2026
    Primary Completion
    Mar 2029est.
    Completion
    Jan 2030est.
    NCT07775287
  • Phase 3
    Not yet recruiting

    Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer

    Rina-S, Bevacizumab

    Ovarian Cancer

    Enrollment
    602
    Start
    Nov 2026est.
    Primary Completion
    Mar 2030est.
    Completion
    Jul 2034est.
    NCT07859215
  • Phase 2/3
    Terminated

    Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

    HuMax-CD4, Placebo

    Rheumatoid Arthritis

    Enrollment
    83
    Start
    Mar 2002
    Primary Completion
    Mar 2003
    Completion
    Mar 2003
    NCT00042406
  • Phase 2
    Completed

    Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

    HuMax-CD4, HuMax-CD4

    Cutaneous T-Cell Lymphoma

    Enrollment
    25
    Start
    Apr 2003
    Primary Completion
    May 2004
    Completion
    May 2004
    NCT00071071
  • Phase 2
    Completed

    Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

    HuMax-CD4, HuMax-CD4

    Cutaneous T-Cell Lymphoma

    Enrollment
    22
    Start
    May 2003
    Primary Completion
    Jun 2004
    Completion
    Jun 2004
    NCT00071084
  • Phase 2
    Terminated

    Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

    Zalutumumab, Induction chemotherapy

    Non Small Cell Lung Cancer

    Enrollment
    13
    Start
    Apr 2007
    Primary Completion
    Oct 2008
    Completion
    Oct 2008
    NCT00460551
  • Phase 2
    Completed

    Zalutumumab in Non-curable Patients With SCCHN

    Zalutumumab

    Head and Neck Cancer, Squamous Cell Cancer

    Enrollment
    90
    Start
    Jan 2008
    Primary Completion
    Aug 2011
    Completion
    Aug 2011
    NCT00542308
  • Phase 2
    Withdrawn

    Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors

    zalutumumab

    Non-small Cell Lung Cancer

    Enrollment
    0
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT01449357
  • Phase 2
    Terminated

    Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

    Acasunlimab, Pembrolizumab

    Non Small Cell Lung Cancer Metastatic

    Enrollment
    125
    Start
    Oct 2021
    Primary Completion
    Dec 2024
    Completion
    Aug 2026
    NCT05117242
  • Phase 2
    Active, not recruiting

    A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

    Epcoritamab, Lenalidomide

    Non-Hodgkin Lymphoma

    Enrollment
    264
    Start
    Jun 2022
    Primary Completion
    Nov 2032est.
    Completion
    Nov 2032est.
    NCT05283720
  • Phase 2
    Active, not recruiting

    A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

    Epcoritamab

    Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma

    Enrollment
    184
    Start
    Aug 2022
    Primary Completion
    Mar 2027est.
    Completion
    Mar 2027est.
    NCT05451810

1-25 of 68

Search ClinicalTrials.gov for “Genmab”